By David Tuller, DrPH
Mahana set to announce FDA approval for ineffective IBS program
Earlier this year, I spent a lot of time blogging about the unethical and dishonest manner in which a San Francisco start-up called Mahana Therapeutics was promoting an eight-week web-based program of cognitive behavior therapy for patients suffering from irritable bowel syndrome. The company had recently licensed this product from King’s College London and was seeking marketing approval in the US and the UK.
[Read more…] about Trial by Error: FDA Approves Web-CBT for IBS; GET/CBT as Tomorrow’s “Rubbish”